Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Thopaz+ portable digital system for managing chest drains: a NICE medical technology guidance

Evans, James Michael, Ray, Alistair ORCID:, Dale, Megan, Morgan, Helen, Dimmock, Paul and Carolan-Rees, Grace 2019. Thopaz+ portable digital system for managing chest drains: a NICE medical technology guidance. Applied Health Economics and Health Policy 17 (3) , 285 -294. 10.1007/s40258-019-00461-y

[thumbnail of Evans2019_Article_ThopazPortableDigitalSystemFor.pdf]
PDF - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (734kB) | Preview


The Thopaz+ portable digital system was evaluated by the Medical Technologies Advisory Committee (MTAC) of the National Institute for Health and Care Excellence (NICE). The manufacturer, Medela, submitted a case for the adoption of Thopaz+ that was critiqued by Cedar, on behalf of NICE. Due to a lack of clinical evidence submitted by the manufacturer, Cedar carried out its own literature search. Clinical evidence showed that the use of Thopaz+ led to shorter drainage times, a shorter hospital stay, lower rates of chest drain re-insertion and higher patient satisfaction compared to conventional chest drainage when used in patients following pulmonary resection. One comparative study of the use of Thopaz+ in patients with spontaneous pneumothorax was identified and showed shorter drainage times and a shorter length of hospital stay compared to conventional drainage. No economic evidence was submitted by the manufacturer, but a simple decision tree model was included. The model was improved by Cedar and showed a cost saving of £111.33 per patient when Thopaz+ was used instead of conventional chest drainage in patients following pulmonary resection. Cedar also carried out a sub-group analysis of the use of Thopaz+ instead of conventional drainage in patients with pneumothorax where a cost saving of £550.90 was observed. The main cost driver for the model and sub-group analysis was length of stay. The sub-group analysis was based on a single comparative study. However, the MTAC received details of an unpublished audit of Thopaz+ which confirmed its efficacy in treating patients with pneumothorax. Thopaz+ received a positive recommendation in Medical Technologies Guidance 37.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Engineering
Publisher: Adis / Springer Verlag
ISSN: 1175-5652
Date of First Compliant Deposit: 19 March 2019
Date of Acceptance: 23 January 2019
Last Modified: 05 Jan 2024 03:17

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics